ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Xiaofan Guo

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5123493852. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2026: 2 papers

Papers 2

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance. Co-author DOI 10.1002/advs.202507346 ↗
Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Co-author DOI 10.1038/s41392-026-02641-4 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiuchao Wang · 2 shared papers, 2026 · strength 0.46
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Yongjie Xie · 2 shared papers, 2026 · strength 0.46
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Jihui Hao · 2 shared papers, 2026 · strength 0.46
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Shengyu Yang · 1 shared paper, 2026 · strength 0.24
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
Yunzhan Li · 1 shared paper, 2026 · strength 0.24
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
Zekun Li · 1 shared paper, 2026 · strength 0.24
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
Chao Xu · 1 shared paper, 2026 · strength 0.24
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
Junjin Wang · 1 shared paper, 2026 · strength 0.24
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
Tianxing Zhou · 1 shared paper, 2026 · strength 0.24
- Paper Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenan… DOI 10.1002/advs.202507346 ↗
Xuan Zhou · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Chuntao Gao · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Tiansuo Zhao · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Jun Yu · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.